Arvinas
ARVN
198 hedge funds and large institutions have $1.47B invested in Arvinas in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 79 increasing their positions, 53 reducing their positions, and 35 closing their positions.
315% more call options, than puts
Call options by funds: $30.8M | Put options by funds: $7.41M
49% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 53
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
5.98% more ownership
Funds ownership: 105.46% → 111.45% (+6%)
4% less funds holding
Funds holding: 206 → 198 (-8)
17% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 35
18% less capital invested
Capital invested by funds: $1.78B → $1.47B (-$313M)
Top Buyers
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$53.7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$38.1M |
| 3 |
RI
RTW Investments
New York
|
+$13.4M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$12.9M |
| 5 |
Morgan Stanley
New York
|
+$11.6M |
Top Sellers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$57.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$32.2M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$31.6M |
| 4 |
CC
Commodore Capital
New York
|
-$29.6M |
| 5 |
JP Morgan Chase
New York
|
-$11.5M |
ARVN Hedge Fund Activity: Q4 2024 in Review
198 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Arvinas (ARVN) for Q4 2024, worth a combined $1.47B — down 18% from $1.78B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of ARVN and 29 opened new positions — a net loss of 6 holders — while 53 trimmed existing stakes and 79 added.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $53.7M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $57.6M sold.
- 198 institutional investors held Arvinas (ARVN) as of Q4 2024, down from 206 in Q3 2024.
- Funds reported $1.47B of Arvinas stock for Q4 2024, down 18% quarter-over-quarter.
- 29 funds opened new Arvinas positions in Q4 2024 and 35 closed out, a net change of -6 holders.
- The largest Arvinas buyer in Q4 2024 was T. Rowe Price Investment Management, an estimated $53.7M added.
- The largest Arvinas seller in Q4 2024 was Paradigm Biocapital Advisors, an estimated $57.6M sold.
Based on aggregated 13F filings for Q4 2024.